Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans

Per L Katzman; Ratna Bose; Stephen Henry; Donna L McLean; Shaun Walker; Christopher Fyfe; Yvette Perry; David Mymin; Peter Bolli

doi:10.1055/s-0038-1642494

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1994; 71(05): 627-632
DOI: 10.1055/s-0038-1642494

Review Article

Schattauer GmbH Stuttgart

Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans

Per L Katzman

¹The Department of Medicine, Section of Nephrology, Winnipeg, Canada

,

Ratna Bose

²The Department of Pharmacology and Therapeutics, Winnipeg, Canada

,

Stephen Henry

¹The Department of Medicine, Section of Nephrology, Winnipeg, Canada

,

Donna L McLean

³The Department of Medicine, Lipid Clinic, Winnipeg, Canada

,

Shaun Walker

¹The Department of Medicine, Section of Nephrology, Winnipeg, Canada

,

Christopher Fyfe

²The Department of Pharmacology and Therapeutics, Winnipeg, Canada

,

Yvette Perry

¹The Department of Medicine, Section of Nephrology, Winnipeg, Canada

,

David Mymin

³The Department of Medicine, Lipid Clinic, Winnipeg, Canada

,

Peter Bolli

¹The Department of Medicine, Section of Nephrology, Winnipeg, Canada

› Author Affiliations

Abstract

PDF Download

Summary

The effects of thrombin (0.2 U/ml) and native (n-LDL), malon- dialdehyde-modified (MDA-LDL) and auto-oxidized (ox-LDL) low-density lipoproteins (20 μg of protein/ml) on platelet activation were evaluated in seven hyperlipidemic patients and compared to seven controls (fasting serum cholesterol 8.49 ± 0.5 and 4.61 ± 0.4 mM, respectively). Basal and thrombin-induced increases in platelet intracellular free calcium ion concentration ([Ca²⁺; fura-2) were similar in hyperlipidemic patients and controls (45 ± 5 vs 42 ± 3 and 635 ±51 vs 599 ± 69 mM, respectively). n-LDL, MDA-LDL and ox-LDL increased basal [Ca²⁺]; (16, 36 and 81 percent, p <0.01 between LDL-types), increases were consistently smaller in patients. There was an inverse relationship between LDL-induced responses and fasting serum LDL cholesterol as well as LDL/HDL ratio.

In conclusion, modified LDL activated platelets to a greater extent than n-LDL, suggesting different types of LDL-receptors. Their agonistic effect was inversely related to the fasting serum lipid profile, suggesting that blunting of platelet responses to LDL could represent a protective mechanism in hyperlipidemic patients.

PDF (586 kb)

References

References
1 Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol lipoproteins, and the risk of coronary heart disease. Ann Int Med 1971; 74: 1-12
2 Bilheimer DW, Ho YK, Brown MS, Anderson RGW, Goldstein JL. Genetics of the low density lipoprotein receptor. J Clin Invest 1978; 61: 678-96
3 Ross R. The pathogenesis of atherosclerosis – an update. N Engl J Med 1986; 314: 488-500
4 Witztum JL. The role of monocytes and oxidized LDL in atherosclerosis. Atherosclerosis Reviews 1990; 21: 59-69
5 Marcus AJ. Recent progress in the role of platelets in occlusive vascular disease. Stroke 1983; 14: 475-9
6 Knorr M, Locher R, Vogt E, Vetter W, Block LH, Ferracin F, Lefkovits H, Pletscher A. Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Eur J Biochem 1988; 172: 753-9
7 Bochkov VN, Rozhkova TA, Matchin YuG, Lyakishev AA, Bochkova NA, Borisova YuL, Kukharchuk VV, Tkachuk VA. LDL- and agonist- induced Ca²⁺-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. Thromb Res 1991; 61: 403-9
8 Katzman PL, Bose R, Walker S, Perry Y, Bolli B. Temperature-dependence of LDL binding and activation of human platelets. Thromb Res 1991; 64: 503-8
9 Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8
10 Brook G, Winterstein G, Aviram M. Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia. Cli Sci 1983; 64: 637-42
11 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24
12 Ylä-Herttuala S. Biochemistry of the arterial wall in developing atherosclerosis. Ann N Y Acad Sci 1991; 623: 40-59
13 Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor- mediated recognition of malondialdehyde-modified low lipoproteins. Proc Natl Acad Sci USA 1982; 79: 1712-16
14 Esterbauer H, Jurgens G, Quehenberger O, Roller K. Autooxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28: 495-509
15 Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 1976; 88: 167-72
16 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
17 Erne P, Bolli P, Burgisser E, Buhler FR. Correlation of platelet calcium with blood pressure; Effect of antihypertensive therapy. N Engl J Med 1984; 310: 1084-8
18 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50
19 Oshima T, Young EW, Bukosi RD, McCarron DA. Abnormal calcium handling by platelets of spontaneously hypertensive rats. Hypertension 1990; 5: 606-11
20 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53
21 Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-24
22 Schuh J, Fairclough GF, Haschemeyer RH. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc Natl Acad Sci USA 1978; 75: 3173-8
23 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-75
24 Lee DM. Malondialdehyde formation in stored plasma. Biochem Biophys Res Commun 1980; 95: 1663-72
25 Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883-7
26 Ball RY, Bindman JP, Carpenter KLH, Mitchinson MJ. Oxidized low density lipoprotein induces ceroid accumulation by murine peritoneal macrophages in vitro. Atherosclerosis 1986; 60: 173-81
27 Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-6
28 Friedman RJ, Stemerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML, Spaet TH. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-201
29 Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine- induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-9
30 Haberland ME, Fogelman AM. The role of altered lipoproteins in the pathogenesis of atherosclerosis. Am Heart J 1987; 113: 573-7
31 Aviram M, Dankner G, Brook JG. Platelet secretory products increase low density lipoprotein oxidation enhance its uptake by macrophages and reduce its fluidity. Arteriosclerosis 1990; 10: 559-63
32 Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-8
33 Harats D, Ben-Naim M, Dabach Y, Hollander G, Havivi E, Stein O, Stein Y. Effects of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990; 85: 47-54
34 Loeper J, Goy J, Rozensztajn L, Bedu O, Moisson P. Lipid peroxidation and protective enzymes during myocardial infarction. Clin Chim Acta 1991; 196: 119-26
35 Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8: 79-87
36 Meraji S, Moore CE, Skinner VO, Bruckdorfer KR. The importance of oxidation or glycosylation of low-denity lipoproteins in relation to platelet activation. Platelets 1992; 3: 155-62
37 van Driel IR, Brown MS, Goldstein JL. Stoichiometric binding of low density lipoprotein (LDL) and monoclonal antibodies to LDL receptors in a solid phase assay. J Biol Chem 1989; 264: 9533-8
38 Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains a-helical and collagen-like coiled coils. Nature 1990; 343: 531-5
39 Rohrer L, Freeman M, Kodama T, Penman M, Krieger M. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature 1990; 343: 570-2
40 Heagerty ANJ, Ollerenshaw JD. The phosphoinositide signalling system and hypertension. J Hypertens 1987; 5: 515-24
41 Roller E, Roller F, Doleschel W. Specific binding sites on human blood platelets for plasma lipoproteins. Hoppe-Seyler Z Physiol Chem 1982; 363: 395-405
42 Sachinidis A, Focher R, Vetter W. Generation of intracellular signals by low density lipoprotein is independent of the classical FDL receptor. Am J Hypertens 1991; 4: 274-9
43 Brown SM, Goldstein LJ. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-7
44 Galle J, Liickhoff A, Busse R, Bassenge E. Fow-density lipoproteins stimulate internal free calcium and prostacyclin release in endothelial cells. Eicosanoids 1990; 3: 81-6
45 Kuzuya M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F. Fipid peroxide and transition metals are required for the toxicity of oxidized low density lipoprotein to cultured endothelial cells. Biochim Biophys Acta 1991; 1096: 155-61
46 Shattil SJ, Anaya-Galindo R, Bennett J. et al. Platelet hypersentivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636